Evidence method
Level · gp.fundamentals.debt_to_revenue
196.39% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ALNY · Jun 30, 2021
ALNYLAM PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001178670-21-000024General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
5.10% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-55.25% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
112.15% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
38.25% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
86.28% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-66.27% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
82.81% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
14.54% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History31 statesSelf-history eligible
Jun 30, 20218/9 normalizedLevel 3Sep 30, 20218/9 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/9 normalizedLevel 3Jun 30, 20228/9 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 107.90%
- Current
- 196.39%
- Delta
- 88.50%
- Previous
- 9.67%
- Current
- 5.10%
- Delta
- -4.58%
- Previous
- -132.72%
- Current
- -55.25%
- Delta
- 77.47%
- Previous
- 78.50%
- Current
- 112.15%
- Delta
- 33.65%
- Previous
- 41.64%
- Current
- 38.25%
- Delta
- -3.39%
- Previous
- 87.03%
- Current
- 86.28%
- Delta
- -0.75%
- Previous
- -104.89%
- Current
- -66.27%
- Delta
- 38.62%
- Previous
- 104.69%
- Current
- 82.81%
- Delta
- -21.89%
- Previous
- 31.36%
- Current
- 14.54%
- Delta
- -16.82%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ALNY Fundamental State →Analogous To · ALNY state analogue 4 →Has State · ALNYLAM PHARMACEUTICALS, INC. →Transitioned To · ALNY Fundamental State →Transitioned To · ALNY BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · ALNY CAPEX_INTENSITY_DECREASED →Transitioned To · ALNY CASH_GENERATION_INCREASED →Transitioned To · ALNY GROWTH_INCREASED →Transitioned To · ALNY INVENTORY_PRESSURE_DECREASED →Transitioned To · ALNY MARGIN_DECREASED →Transitioned To · ALNY PROFITABILITY_INCREASED →Transitioned To · ALNY R_AND_D_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.